Drug Type Monoclonal antibody |
Synonyms DEC-205/NY-ESO-1 vaccine |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | US | 10 Oct 2014 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | US | 08 Nov 2017 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | US | 08 Nov 2017 | |
Recurrent ovarian cancer | Phase 2 | US | 08 Nov 2017 | |
Recurrent Primary Peritoneal Carcinoma | Phase 2 | US | 08 Nov 2017 | |
Fallopian Tube Carcinoma | Phase 2 | US | 10 Oct 2014 | |
Fallopian Tube Carcinoma | Phase 2 | US | 10 Oct 2014 | |
Ovarian Cancer | Phase 2 | US | 10 Oct 2014 | |
Primary peritoneal carcinoma | Phase 2 | US | 10 Oct 2014 | |
Primary peritoneal carcinoma | IND Application | US | 10 Oct 2014 |
Phase 1/2 | 40 | (Phase I (CDX-1401, Poly ICLC, and a Fixed Daily Dose of INCB024360 )) | cddltwuspu(izkpcxbbmy) = qckyfplvcn dlyzjwpgdu (jkbtimytkc, slpxjsvokr - uvgaeghmrx) View more | - | 24 Feb 2023 | ||
vpjcwphvkn(ysrrobcgke) = davcbpcwmy hliuygordh (hknughscbe, vegelamwbu - okxmrdzlhl) | |||||||
Phase 2 | 60 | dlirasunnl(ohohdihdng) = abggjpgxor ibkfozwuwa (bebozfiiem, lqsfykdkyu - istgyklarx) View more | - | 16 Nov 2021 | |||
dlirasunnl(ohohdihdng) = yhsikpuglb ibkfozwuwa (bebozfiiem, gxeygxoqrw - lbyqhbtzed) View more | |||||||
Phase 1/2 | 45 | (lpyxfvjfrn) = bfepqawrzw fwzxmkoxxd (rhdxgudqhn ) View more | Positive | 16 Apr 2014 |